Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 6
2008 2
2009 3
2010 3
2011 4
2012 5
2013 5
2014 3
2015 5
2016 1
2017 3
2018 9
2019 12
2020 14
2021 7
2022 10
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Novel and emerging treatment options for acne vulgaris.
Auffret N, Claudel JP, Leccia MT, Ballanger F, Dreno B. Auffret N, et al. Among authors: leccia mt. Eur J Dermatol. 2022 Jul 1;32(4):451-458. doi: 10.1684/ejd.2022.4306. Eur J Dermatol. 2022. PMID: 36301760 Review. English.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
New Vision in Photoprotection and Photorepair.
Leccia MT, Lebbe C, Claudel JP, Narda M, Basset-Seguin N. Leccia MT, et al. Dermatol Ther (Heidelb). 2019 Mar;9(1):103-115. doi: 10.1007/s13555-019-0282-5. Epub 2019 Jan 23. Dermatol Ther (Heidelb). 2019. PMID: 30674003 Free PMC article. Review.
Efficacy of imiquimod in the management of lentigo maligna.
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis MG, Bossard C, Vergier B, Khammari A, Dréno B. Daude M, et al. Among authors: leccia mt. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1785-1791. doi: 10.1111/jdv.19141. Epub 2023 May 6. J Eur Acad Dermatol Venereol. 2023. PMID: 37114291 Clinical Trial.
Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.
Dréno B, Nguyen JM, Hainaut E, Machet L, Leccia MT, Beneton N, Claudel JP, Célérier P, Le Moigne M, Le Naour S, Vrignaud F, Poinas A, Dert C, Boisrobert A, Flet L, Korner S, Khammari A. Dréno B, et al. Among authors: leccia mt. Acta Derm Venereol. 2024 Feb 21;104:adv26002. doi: 10.2340/actadv.v104.26002. Acta Derm Venereol. 2024. PMID: 38380975 Free PMC article. Clinical Trial.
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis.
Cordel N, Flament J, Jouen F, Seta V, Tancrède-Bohin E, Dahan CP, Konstantinou MP, Dereure O, Quéreux G, Prost C, Bedane C, Debarbieux S, Lacour JP, Dompmartin A, Wierzbicka-Hainaut E, Villada IB, Oro SIH, Vabres P, Richard MA, Delaporte E, Pham-Ledard A, Leccia MT, Litrowski N, Michel C, Lagrange B, D'Incan M, Abasq C, Duvert-Lehembre S, Dupuy A, Alcaraz I, Breton-Guitarian AL, Lombart F, Estève E, Machet L, Del Giudice P, Fenot M, Belmondo T, Morin F, Guérin O, Benichou J, Tressières B, Joly P; French study Group on autoimmune bullous skin diseases. Cordel N, et al. Among authors: leccia mt. J Eur Acad Dermatol Venereol. 2023 Jun;37(6):1207-1214. doi: 10.1111/jdv.18973. Epub 2023 Mar 6. J Eur Acad Dermatol Venereol. 2023. PMID: 36802102
Defining and recognising locally advanced basal cell carcinoma.
Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B, Falandry C, Froget N, Giacchero D, Grob JJ, Guerreschir P, Leccia MT, Malard O, Mortier L, Routier E, Stefan A, Stefan D, Stoebner PE, Basset-Seguin N. Amici JM, et al. Among authors: leccia mt. Eur J Dermatol. 2015 Nov-Dec;25(6):586-94. doi: 10.1684/ejd.2015.2641. Eur J Dermatol. 2015. PMID: 26574792 Review.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: leccia mt. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.
92 results